Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK.
Khuri FR, et al.
J Natl Cancer Inst. 2006 Apr 5;98(7):441-50. doi: 10.1093/jnci/djj091.
J Natl Cancer Inst. 2006.
PMID: 16595780
Clinical Trial.